What were Kopran Ltd's latest quarterly results?
Kopran Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -10.2%
- Revenue Growth YoY: +16.9%
- Operating Margin: 9.1%
Kopran Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 33.1. ROE: 7.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Kopran Ltd's latest quarterly results (Dec 2025) show
Kopran Ltd's current PE ratio is 33.1x.
Kopran Ltd's price-to-book ratio is 1.1x.
Kopran Ltd's fundamental strength based on key financial ratios
Kopran Ltd has a debt-to-equity ratio of N/A.
Kopran Ltd's return ratios over recent years
Kopran Ltd's operating cash flow is positive (FY2025).
Kopran Ltd's current dividend yield is 2.64%.
Kopran Ltd's shareholding pattern (Dec 2025)
Kopran Ltd's promoter holding has remained stable recently.
Kopran Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Kopran Ltd may be worth studying
Kopran Ltd investment thesis summary:
Kopran Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.